Cat food recalled due to possible bird flu contamination
Another U.S.-based cat food brand has recalled its products due to the possibility of contamination with bird flu.
On Saturday, Wild Coast LLC dba Wild Coast Raw announced a recall on its frozen Boneless Free Range Chicken Formula raw pet food for cats.
According to a notice shared by the Food and Drug Administration (FDA), the recall is due to the possibility that the pet food was contaminated with bird flu, also known as Highly Pathogenic Avian Influenza (HPAI) H5N1.
The affected products came in 16-ounce or 24-ounce packaging and were sold at pet food retailers in Washington and Oregon. The frozen products came in a small round white plastic container with a green label on it.
Recalled cat food containers can be identified with the numbers of 22660, 22653, 22641, 22639, 22672 and 22664, and the Best By date of December 25. This recall also affects any 'raw material sharing similar production dates and lot codes as 22660 and 22664.'
This recall was initiated after sampling by the Oregon Department of Agriculture revealed 'the presence of the same strain of H5N1 in the affected cats and these products as well as sampling by the Washington State Department of Agriculture.'
Although no human infections have been identified, people handling this raw pet food 'can become infected if the virus gets into a person's eyes, nose, or mouth.' The FDA urges pet owners with the cat food to 'watch for symptoms of bird flu, including eye redness or irritation (conjunctivitis), cough, sore throat, sneezing, runny/stuffy nose, and muscle/body aches.'
Wild Coast LLC dba Wild Coast Raw asks anyone who has the recalled product to discard it immediately. They also should not feed the food to any of their pets, and they can contact the store they bought the product from for a full refund.
The American Veterinary Medical Association had previously issued a warning about the bird flu outbreak affecting cats.
'Cats were already known to be susceptible to the H5N1 virus, with several feline cases linked to poultry or wild bird exposure before the outbreak in cattle began,' the organisation said in a statement on its website. 'Cats appear to be particularly susceptible to severe illness, often resulting in death. Whether infected cats can infect other cats is currently unclear; however, that possibility cannot be dismissed.'
The virus has been tearing across the U.S. in recent months, resulting in the culling of millions of birds, sending egg prices skyrocketing, infecting dozens of humans, and killing one person in Louisiana. H5N1 does not have the ability to transmit from person to person, researchers say, and health officials have stressed that the risk to humans remains mild.
The latest recall comes after Portland-based pet food company Northwest Naturals issued a North American recall in December after a cat died from consuming a batch of their cat food, which was contaminated with bird flu. At the time, the company recalled its two-pound Feline Turkey Recipe raw frozen pet food.
According to the ODA's press release, laboratory testing conducted by the U.S. Department of Agriculture and Oregon State University confirmed that the cat contracted H5N1 and died after consuming the raw frozen pet food. These tests also confirmed a genetic match between the virus found in the pet food and the virus that infected the cat.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Global Healthy Living Foundation Says Vaccine Committee Firings Before Respiratory Virus Season Creates High Risk Of Illness In the Chronic Disease Community
HHS Interrupts "The Most Cost-Beneficial Intervention In Healthcare" UPPER NYACK, N.Y., June 10, 2025--(BUSINESS WIRE)--Yesterday, the Secretary of Health and Human Services (HHS) removed all sitting members of the Advisory Committee on Immunization Practices (ACIP), the expert panel that advises the Centers for Disease Control and Prevention (CDC) on vaccine use. While the groups such as the Global Healthy Living Foundation (GHLF) recognize the Secretary's right to do this, the decision made just ahead of the upcoming respiratory virus season puts at risk chronically ill patients who rely on vaccines to fight respiratory virus infections. ACIP is often critical in shaping public health strategies with its advisory recommendations. While the FDA-approved label remains the definitive, enforceable standard for how vaccines should be used in clinical practice, ACIP guidance often informs insurance company coverage, determines whether vaccines are free under the Affordable Care Act, provides healthcare provider protocols, and helps ensure vaccination campaign success , especially for vulnerable populations. "Removing the entire committee without immediate replacement or clear guidance creates uncertainty when COVID-19, flu, and RSV are expected to circulate widely in the coming months," said Robert, Popovian, PharmD, MS, GHLF's Chief Science Policy Officer. "Now is the time when the advisory committee makes its recommendations, and disruption in the advisory process could have profound implications for individuals with chronic illnesses who depend on timely vaccine access to protect themselves against these viruses. "We support the need for ACIP to remain independent, and we recognize the Secretary's authority to appoint new members," Dr. Popovian added. "But removing all members without naming successors or offering a timeline to replace them so close to respiratory season could delay essential recommendations. "Vaccines are the most cost-beneficial intervention in healthcare—we should do everything possible to maintain uninterrupted access to expert guidance including ensuring there is no gap in expert advice during this critical period for immunization planning," Dr. Popovian added. About GHLF The Global Healthy Living Foundation is a U.S. based, 501(c)(3) nonprofit, international organization whose mission is to improve the quality of life for people with chronic illnesses by advocating for improved access to health care through education, patient-centered clinical research, support, advocacy, and economic and policy research. GHLF is also a staunch advocate for vaccines. The Global Healthy Living Foundation is the parent organization of CreakyJoints®, the international, digital community for millions of people living with arthritis and their supporters worldwide who seek education, support, activism, and patient-centered research in English, Spanish, and French. In addition to arthritis and autoimmune disorders, GHLF supports dermatology, gastroenterology, neurology, cardiology, oncology, infectious disease, rare disease, and pulmonary patients through a host of different programs and activities which draw more than 700,000 patients a month to GHLF websites and create more than 10 million impressions a month on seven social media platforms. In 2024, GHLF had more than 1 million views and listens with its patient-centered audio-visual content, found on YouTube and podcast platforms. GHLF never asks the public for donations, receiving funding instead through governments, non-governmental organizations, foundations, industry, family foundations, and GHLF Co-Founder Louis Tharp. Visit for more information. View source version on Contacts Louis TharpLTHARP@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
an hour ago
- Business Wire
Global Healthy Living Foundation Says Vaccine Committee Firings Before Respiratory Virus Season Creates High Risk Of Illness In the Chronic Disease Community
BUSINESS WIRE)--Yesterday, the Secretary of Health and Human Services (HHS) removed all sitting members of the Advisory Committee on Immunization Practices (ACIP), the expert panel that advises the Centers for Disease Control and Prevention (CDC) on vaccine use. Vaccines are the most cost-beneficial intervention in healthcare While the groups such as the Global Healthy Living Foundation (GHLF) recognize the Secretary's right to do this, the decision made just ahead of the upcoming respiratory virus season puts at risk chronically ill patients who rely on vaccines to fight respiratory virus infections. ACIP is often critical in shaping public health strategies with its advisory recommendations. While the FDA-approved label remains the definitive, enforceable standard for how vaccines should be used in clinical practice, ACIP guidance often informs insurance company coverage, determines whether vaccines are free under the Affordable Care Act, provides healthcare provider protocols, and helps ensure vaccination campaign success , especially for vulnerable populations. 'Removing the entire committee without immediate replacement or clear guidance creates uncertainty when COVID-19, flu, and RSV are expected to circulate widely in the coming months,' said Robert, Popovian, PharmD, MS, GHLF's Chief Science Policy Officer. 'Now is the time when the advisory committee makes its recommendations, and disruption in the advisory process could have profound implications for individuals with chronic illnesses who depend on timely vaccine access to protect themselves against these viruses. 'We support the need for ACIP to remain independent, and we recognize the Secretary's authority to appoint new members,' Dr. Popovian added. 'But removing all members without naming successors or offering a timeline to replace them so close to respiratory season could delay essential recommendations. 'Vaccines are the most cost-beneficial intervention in healthcare—we should do everything possible to maintain uninterrupted access to expert guidance including ensuring there is no gap in expert advice during this critical period for immunization planning,' Dr. Popovian added. About GHLF The Global Healthy Living Foundation is a U.S. based, 501(c)(3) nonprofit, international organization whose mission is to improve the quality of life for people with chronic illnesses by advocating for improved access to health care through education, patient-centered clinical research, support, advocacy, and economic and policy research. GHLF is also a staunch advocate for vaccines. The Global Healthy Living Foundation is the parent organization of CreakyJoints®, the international, digital community for millions of people living with arthritis and their supporters worldwide who seek education, support, activism, and patient-centered research in English, Spanish, and French. In addition to arthritis and autoimmune disorders, GHLF supports dermatology, gastroenterology, neurology, cardiology, oncology, infectious disease, rare disease, and pulmonary patients through a host of different programs and activities which draw more than 700,000 patients a month to GHLF websites and create more than 10 million impressions a month on seven social media platforms. In 2024, GHLF had more than 1 million views and listens with its patient-centered audio-visual content, found on YouTube and podcast platforms. GHLF never asks the public for donations, receiving funding instead through governments, non-governmental organizations, foundations, industry, family foundations, and GHLF Co-Founder Louis Tharp. Visit for more information.
Yahoo
an hour ago
- Yahoo
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. WALTHAM, Mass. & GENEVA, Switzerland, June 10, 2025--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections and the World Health Organization (WHO) identifying antimicrobial resistance (AMR) as one of the ten most critical global threats to public health, the bacterium Neisseria gonorrhoeae has progressively developed resistance to many classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. "Today's acceptance of the zoliflodacin NDA marks significant progress toward delivering health care providers with a potential new oral treatment option for uncomplicated gonorrhea, including infections caused by drug-resistant strains," said David Altarac, M.D., Chief Medical Officer, Innoviva Specialty Therapeutics. "We look forward to working closely with the FDA during its review and, if approved, we are committed to expediting the availability of zoliflodacin to patients in the U.S." Recent reports (The Lancet Infectious Diseases) of emergent ceftriaxone-resistant infections have heightened the urgency for new antibiotics. Effective treatment options are essential to reducing the burden of disease for individuals and preventing the spread of highly drug-resistant gonorrhea globally. If left untreated, gonorrhea can also cause infertility in women, life-threatening ectopic pregnancies, and pelvic inflammatory disease.2 The FDA's acceptance of the zoliflodacin NDA is based on the totality of data collected from several clinical trials as part of an innovative public-private partnership with GARDP. These trials include a pivotal Phase 3 clinical trial which demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection of a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of ceftriaxone followed by 1 week of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. "This important milestone demonstrates the crucial role that public-private partnerships can play in tackling the escalating global antimicrobial resistance crisis," said Dr. Manica Balasegaram, Executive Director, Global Antibiotic Research Development Partnership (GARDP). "If zoliflodacin is approved, this collaboration paves the way for millions of people across the world to get access to a potentially powerful new drug to treat multidrug-resistant gonorrhea." Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In vitro studies have demonstrated its activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. This investigational antibacterial is administered in a single, oral dose, simplifying treatment by providing a convenient option for patients unable to receive an intramuscular injection. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Innoviva Specialty Therapeutics, Inc., anticipates that the NDA review will proceed according to the standard process for drugs with this designation. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. On December 14, 2024, Innoviva entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to View source version on Contacts Media Contacts:Innoviva Specialty TherapeuticsDavid +1.908.421.5971GARDPDuncan Graham-Rowedgrahamrowe@ +44 7966 413623 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data